{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:04:08Z","timestamp":1789128248113,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26502-2","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:26:41Z","timestamp":1764250001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation"],"prefix":"10.1038","volume":"15","author":[{"given":"Magdalena","family":"Rogalska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"B\u0142achnio-Zabielska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Zabielski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Janica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Roszczyc-Owsiejczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Pogodzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Andrzejuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"D\u0105browski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Rogalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"26502_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000179","volume":"7","author":"J Trivella","year":"2023","unstructured":"Trivella, J., John, B. V. & Levy, C. Primary biliary cholangitis: Epidemiology, prognosis, and treatment. Hepatol. Commun. 7, e0179 (2023).","journal-title":"Hepatol. Commun."},{"key":"26502_CR2","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.3748\/wjg.v11.i36.5706","volume":"11","author":"R Flisiak","year":"2005","unstructured":"Flisiak, R., Pelszynska, M., Prokopowicz, D., Rogalska, M. & Grygoruk, U. High concentration of antimitochondrial antibodies predicts progressive primary biliary cirrhosis. World J. Gastroenterol. 11, 5706\u20135709 (2005).","journal-title":"World J. Gastroenterol."},{"key":"26502_CR3","doi-asserted-by":"publisher","first-page":"e35617","DOI":"10.1097\/MD.0000000000035617","volume":"102","author":"Y Jin","year":"2023","unstructured":"Jin, Y., Wang, M., Liu, Y. & Xu, A. Antimitochondrial antibody associated with liver cirrhosis in patients with primary biliary cholangitis. Medicine 102, e35617 (2023).","journal-title":"Medicine"},{"key":"26502_CR4","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1053\/j.gastro.2024.01.049","volume":"166","author":"PJ Trivedi","year":"2024","unstructured":"Trivedi, P. J., Hirschfield, G. M., Adams, D. H. & Vierling, J. M. Immunopathogenesis of primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis: Themes and concepts. Gastroenterology 166, 995\u20131019 (2024).","journal-title":"Gastroenterology"},{"key":"26502_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102328","volume":"105","author":"B Terziroli Beretta-Piccoli","year":"2019","unstructured":"Terziroli Beretta-Piccoli, B. et al. The challenges of primary biliary cholangitis: What is new and what needs to be done. J. Autoimmun. 105, 102328 (2019).","journal-title":"J. Autoimmun."},{"key":"26502_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol. 67, 145\u2013172 (2017).","journal-title":"J. Hepatol."},{"key":"26502_CR7","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/17474124.2022.2153672","volume":"16","author":"LX Huang","year":"2022","unstructured":"Huang, L. X., Wang, Z. L., Jin, R., Chen, H. S. & Feng, B. Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: Criteria, epidemiology, and possible mechanisms. Expert Rev. Gastroenterol. Hepatol. 16, 1065\u20131078 (2022).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"26502_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrm.2017.107","volume":"19","author":"YA Hannun","year":"2018","unstructured":"Hannun, Y. A. & Obeid, L. M. Sphingolipids and their metabolism in physiology and disease. Nat. Rev. Mol. Cell Biol. 19, 175\u2013191 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"26502_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1515\/hsz-2014-0296","volume":"396","author":"H Nojima","year":"2015","unstructured":"Nojima, H., Freeman, C. M., Gulbins, E. & Lentsch, A. B. Sphingolipids in liver injury, repair and regeneration. Biol. Chem. 396, 633\u2013643 (2015).","journal-title":"Biol. Chem."},{"key":"26502_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1478-3231.2007.01475.x","volume":"27","author":"M Mar\u00ed","year":"2007","unstructured":"Mar\u00ed, M. & Fern\u00e1ndez-Checa, J. C. Sphingolipid signalling and liver diseases. Liver Int. 27, 440\u2013450 (2007).","journal-title":"Liver Int."},{"key":"26502_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12876-020-01190-6","volume":"20","author":"H Miyaaki","year":"2020","unstructured":"Miyaaki, H. et al. Blood carnitine profiling on tandem mass spectrometry in liver cirrhotic patients. BMC Gastroenterol. 20, 41 (2020).","journal-title":"BMC Gastroenterol."},{"key":"26502_CR12","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/rcm.6216","volume":"26","author":"AU Blachnio-Zabielska","year":"2012","unstructured":"Blachnio-Zabielska, A. U., Persson, X. M., Koutsari, C., Zabielski, P. & Jensen, M. D. A liquid chromatography\/tandem mass spectrometry method for measuring the in vivo incorporation of plasma free fatty acids into intramyocellular ceramides in humans. Rapid Commun. Mass Spectrom. 26, 1134\u20131140 (2012).","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"26502_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ultras.2017.02.005","volume":"77","author":"R Mare","year":"2017","unstructured":"Mare, R. et al. The value of ElastPQ for the evaluation of liver stiffness in patients with B and C chronic hepatopathies. Ultrasonics 77, 144\u2013151 (2017).","journal-title":"Ultrasonics"},{"key":"26502_CR14","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1476-5381.2009.00281.x","volume":"158","author":"GF Nixon","year":"2009","unstructured":"Nixon, G. F. Sphingolipids in inflammation: Pathological implications and potential therapeutic targets. Br. J. Pharmacol. 158, 982\u2013993 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"26502_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.tcb.2005.04.006","volume":"15","author":"AH Futerman","year":"2005","unstructured":"Futerman, A. H. & Riezman, H. The ins and outs of sphingolipid synthesis. Trends Cell Biol. 15, 312\u2013318 (2005).","journal-title":"Trends Cell Biol."},{"key":"26502_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/BF02815356","volume":"21","author":"R Kolesnick","year":"1994","unstructured":"Kolesnick, R. Signal transduction through the sphingomyelin pathway. Mol. Chem. Neuropathol. 21, 287\u2013297 (1994).","journal-title":"Mol. Chem. Neuropathol."},{"key":"26502_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1126\/science.2643164","volume":"243","author":"YA Hannun","year":"1989","unstructured":"Hannun, Y. A. & Bell, R. M. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 243, 500\u2013507 (1989).","journal-title":"Science"},{"key":"26502_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.prostaglandins.2007.02.001","volume":"83","author":"P Zabielski","year":"2007","unstructured":"Zabielski, P., Baranowski, M., Zendzian-Piotrowska, M., Blachnio, A. & Gorski, J. Partial hepatectomy activates production of the pro-mitotic intermediates of the sphingomyelin signal transduction pathway in the rat liver. Prostaglandins Other. Lipid Mediat. 83, 277\u2013284 (2007).","journal-title":"Prostaglandins Other. Lipid Mediat."},{"key":"26502_CR19","doi-asserted-by":"publisher","first-page":"20589","DOI":"10.1074\/jbc.M101207200","volume":"276","author":"H Grassme","year":"2001","unstructured":"Grassme, H. et al. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 276, 20589\u201320596 (2001).","journal-title":"J. Biol. Chem."},{"key":"26502_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/1074-7613(95)90142-6","volume":"2","author":"E Gulbins","year":"1995","unstructured":"Gulbins, E. et al. FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity 2, 341\u2013351 (1995).","journal-title":"Immunity"},{"key":"26502_CR21","doi-asserted-by":"publisher","first-page":"E211","DOI":"10.1152\/ajpendo.91014.2008","volume":"297","author":"G Yang","year":"2009","unstructured":"Yang, G. et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 297, E211-224 (2009).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"26502_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.tem.2012.04.005","volume":"23","author":"M Pagadala","year":"2012","unstructured":"Pagadala, M., Kasumov, T., McCullough, A. J., Zein, N. N. & Kirwan, J. P. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol. Metab. 23, 365\u2013371 (2012).","journal-title":"Trends Endocrinol. Metab."},{"key":"26502_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100479","volume":"4","author":"B Paul","year":"2022","unstructured":"Paul, B., Lewinska, M. & Andersen, J. B. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 4, 100479 (2022).","journal-title":"JHEP Rep."},{"key":"26502_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-1-0716-2128-8_22","volume":"2455","author":"D Montefusco","year":"2022","unstructured":"Montefusco, D., Lambert, J., Anderson, A., Allegood, J. & Cowart, L. A. Analysis of the sphingolipidome in NAFLD. Methods Mol. Biol. 2455, 279\u2013303 (2022).","journal-title":"Methods Mol. Biol."},{"key":"26502_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2019.106399","volume":"147","author":"A Mikucka-Niczyporuk","year":"2020","unstructured":"Mikucka-Niczyporuk, A. et al. Role of sphingolipids in the pathogenesis of intrahepatic cholestasis. Prostaglandins Other. Lipid Mediat. 147, 106399 (2020).","journal-title":"Prostaglandins Other. Lipid Mediat."},{"key":"26502_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.bbalip.2013.08.019","volume":"1841","author":"JW Park","year":"2014","unstructured":"Park, J. W., Park, W. J. & Futerman, A. H. Ceramide synthases as potential targets for therapeutic intervention in human diseases. Biochim. Biophys. Acta. 1841, 671\u2013681 (2014).","journal-title":"Biochim. Biophys. Acta."},{"key":"26502_CR27","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3390\/nu17071097","volume":"17","author":"M Rogalska","year":"2025","unstructured":"Rogalska, M. et al. Acylcarnitine and free fatty acid profiles in primary biliary cholangitis: Associations with fibrosis and inflammation. Nutrients 17, 1097 (2025).","journal-title":"Nutrients"},{"key":"26502_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1124\/jpet.108.139808","volume":"327","author":"S Cuzzocrea","year":"2008","unstructured":"Cuzzocrea, S. et al. Anti-inflammatory and anti-apoptotic effects of fumonisin B1, an inhibitor of ceramide synthase, in a rodent model of splanchnic ischemia and reperfusion injury. J. Pharmacol. Exp. Ther. 327, 45\u201357 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"26502_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/FJC.0b013e31819b52d5","volume":"53","author":"SA Novgorodov","year":"2009","unstructured":"Novgorodov, S. A. & Gudz, T. I. Ceramide and mitochondria in ischemia\/reperfusion. J. Cardiovasc. Pharmacol. 53, 198\u2013208 (2009).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"26502_CR30","doi-asserted-by":"publisher","first-page":"27855","DOI":"10.1074\/jbc.R111.254359","volume":"286","author":"YA Hannun","year":"2011","unstructured":"Hannun, Y. A. & Obeid, L. M. Many ceramides. J. Biol. Chem. 286, 27855\u201327862 (2011).","journal-title":"J. Biol. Chem."},{"key":"26502_CR31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/intimm\/dxz037","volume":"31","author":"H Obinata","year":"2019","unstructured":"Obinata, H. & Hla, T. Sphingosine 1-phosphate and inflammation. Int. Immunol. 31, 617\u2013625 (2019).","journal-title":"Int. Immunol."},{"key":"26502_CR32","doi-asserted-by":"publisher","first-page":"32119","DOI":"10.1038\/srep32119","volume":"6","author":"M Sato","year":"2016","unstructured":"Sato, M. et al. Sphingosine kinase-1, S1P transporter spinster homolog 2 and S1P2 mRNA expressions are increased in liver with advanced fibrosis in human. Sci. Rep. 6, 32119 (2016).","journal-title":"Sci. Rep."},{"key":"26502_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jhep.2013.02.021","volume":"59","author":"L Yang","year":"2013","unstructured":"Yang, L. et al. Sphingosine kinase\/sphingosine 1-phosphate (S1P)\/S1P receptor axis is involved in liver fibrosis-associated angiogenesis. J. Hepatol. 59, 114\u2013123 (2013).","journal-title":"J. Hepatol."},{"key":"26502_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.livres.2019.02.003","volume":"3","author":"EK Kwong","year":"2019","unstructured":"Kwong, E. K. & Zhou, H. Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases. Liver Res. 3, 19\u201324 (2019).","journal-title":"Liver Res."},{"key":"26502_CR35","doi-asserted-by":"publisher","first-page":"eaar5551","DOI":"10.1126\/science.aar5551","volume":"366","author":"A Cartier","year":"2019","unstructured":"Cartier, A. & Hla, T. Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. Science 366, eaar5551 (2019).","journal-title":"Science"},{"key":"26502_CR36","doi-asserted-by":"publisher","first-page":"20294","DOI":"10.1038\/s41598-025-07308-8","volume":"15","author":"T Elger","year":"2025","unstructured":"Elger, T. et al. Elevated long-to-very-long-chain ceramide ratio correlates with disease severity in inflammatory bowel disease and primary sclerosing cholangitis. Sci. Rep. 15, 20294 (2025).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26502-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26502-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26502-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:26:42Z","timestamp":1764250002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26502-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26502"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26502-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42502"}}